1. Listgarten MA. Pathogenesis of periodontitis. J Clin Periodontol. 1986 May;13(5):418-30. 2. Newman MG, Takei HH, Klokkevold PR,
Carranza FA. Carranza’s clinical periodontolo-gy. 11thed. Missouri: Elsevier Saunders; 2012,160. 3. Kantarci A, Van Dyke TE. Lipoxin signaling in neutrophils and their role in periodontal disease. Prostagland Leuk Essent Fat Acid. 2005 Sept-Oct; 73(3-4):289-99. 4. Van Dyke TE, Serhan CN. Resolution of
inflammation: A new paradigm for the
pathogenesis of periodontal diseases. J Dent Res. 2003 Feb; 82(2):82-90. 5. Iwasaki M, Yoshihara A, Moynihan P,
Watanabe R, Taylor GW, Miyazaki H.
Longitudinal relationship between dietary ω-3 fatty acids and periodontal disease. Nutrition. 2010 Nov -Dec; 26 (11-12):1105-9. 6. Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Periodontol. 2005;32 Suppl 6:108-29. 7. Bhatavadekar NB, Williams RC. New directions in host modulation for the management of
periodontal disease. J Clin Periodontol. 2009 Feb; 36(2):124-6. 8. Preshaw PM, Hefti AF, Jepsen S, Etienne D, Walker C, Bradshaw MH. Subantimicrobial dose doxycycline as adjunctive treatment for
periodontitis A review. J Clin Periodontol. 2004 Sept; 31(9):697-707. 9. Fleming T. PDR for herbal Medicines. 1st ed. Montvale: Medical Econnomics; 1998. 875-9. 10. Ashley RA. Clinical trials of a matrix
metalloproteinase inhibitor in human periodon-tal disease. SDD Clinical Research Team. Ann N Y Acad Sci. 1999 Jun 30;878:335-46. 11. Caton JG, Ciancio SG, Blieden TM, Bradshaw M, Crout RJ, Hefti AF, et al. Subantimicrobial dose doxycycline as an adjunct to scaling and root planing: post-treatment effects. J Clin Peri-odontol. 2001 Aug;28(8):782-9. 12. Crout RJ, Lee HM, Schroeder K, Crout H,
Ramamurthy NS, Wiener M, et al. The "cyclic" regimen of low-dose doxycycline for adult
periodontitis: a preliminary study. J Periodontol. 1996 May;67(5):506-14. 13. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, et al. Minocycline
reduces gingival collagenolytic activity during
diabetes. Preliminary observations and a pro-posed new mechanism of action. J Periodontal Res. 1983 Sept;18(5):516-26. 14. Kesavalu L, Vasudevan B, Raghu B, Browning E, Dawson D, Novak JM, et al. Omega-3 fatty acid effect on alveolar bone loss in rats. J Dent Res. 2006 Jul;85(7):648-52. 15. Naqvi AZ, Buettner C, Phillips RS, Davis RB, Mukamal KJ. n-3 fatty acids and periodontitis in US adults. J Am Diet Assoc. 2010 Nov; 110(11): 1669-75. 16. Arita M, Clish CB, Serhan CN. The
contributions of aspirin and microbial oxygen-ase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from ome-ga-3
polyunsaturated fatty acids. Biochem Biophys Res Com. 2005 Dec 9;338(1):149-57. 17. Faizuddin M, Tarannum F, Korla N, Swamy S. Association between long-term aspirin use and periodontal attachment level in humans: a
cross-sectional investigation. Aust Dent J. 2012 Mar; 57(1):45-50. 18. Elkhouli AM. The efficacy of host response modulation therapy (omega-3 plus low-dose
aspirin) as an adjunctive treatment of chronic
periodontitis (clinical and biochemical study).
Elkhouli AM. J Periodontal Res. 2011 Apr; 46(2): 261-8. 19. Bendyk A, Marino V, Zilm PS, Howe P,
Bartold PM. Effect of dietary omega-3
polyunsaturated fatty acids on experimental
periodontitis in the mouse. J Periodontal Res. 2009 Apr; 44(2):211-6. 20. Golub LM, Suomalainen K, Sorsa T. Host mod-ulation with tetracyclines and their chemically modified analogues. Curr Opin Dent. 1992 Mar; 2: 80-90. 21. Uitto VJ, Airola K, Vaalamo M, Johansson N, Putnins EE, Firth JD, et al. Collagenase-3 (ma-trix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic in-flammation. Am J Pathol. 1998 Jun;152(6):1489-99. 22. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and
17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation.J Biol Chem. 2003 Apr 25;278(17):14677-87. 23. Serhan CN, Chiang N, Van Dyke TE.
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev
Immunol. 2008 May;8(5):349-61. 24. El-Sharkawy H, Aboelsaad N, Eliwa M,
Darweesh M, Alshahat M, Kantarci A, et al.
Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 Fatty acids and low-dose aspirin. J Periodon-tol. 2010 Nov; 81(11):1635-43. 25. Caton J, Ryan ME. Clinical studies on the man-agement of periodontal diseases utilizing
subantimicrobial dose doxycycline (SDD).
Pharmacol Res. 2011 Feb;63(2):114-20. 26. Golub LM, Lee HM, Stoner JA, Reinhardt RA, Sorsa T, Goren AD, et al. Doxycycline effects on serum bone biomarkers in post-menopausal
women. J Dent Res. 2010 Jun; 89(6):644-9. 27. Payne JB, Golub LM. Using tetracyclines to treat osteoporotic/osteopenic bone loss: From the basic science laboratory to the clinic. Phar-macol Res. 2011 Feb;63(2):121-9. 28. Tüter G, Kurtiş B, Serdar M, Aykan T, Okyay K, Yücel A,et al. Effects of scaling and root
planing and sub-antimicrobial dose doxycycline on oral and systemic biomarkers of disease in patients with both chronic periodontitis and coronary artery disease. J Clin Periodontol. 2007Aug; 34(8):673-81. 29. Akalin FA, Baltacioğlu E, Sengün D,
Hekimoğlu S, Taşkin M, Etikan I, et al. A
comparative evaluation of the clinical effects of systemic and local doxycycline in the treatment of chronic periodontitis. J Oral Sci. 2004 Mar; 46(1): 25-35. 30. Novak MJ, Johns LP, Miller RC, Bradshaw MH. Adjunctive benefits of subantimicrobial dose doxycycline in the management of severe,
generalized, chronic periodontitis. J Periodontol. 2002 Jul; 73(7):762-9.
|